CHG-2023-0102

Formulation Change for Respiralimab. Formulation Change for Respiralimab — routine update. Impacts 6 markets and 5 variations.

Change Number
CHG-2023-0102
Type
Formulation Change
Product
Respiralimab
Status
Pending
Owner
Carlos Mendez
Initiated
2022-11-29
Description

Formulation Change for Respiralimab — routine update

Impacted Markets (6)
US — United StatesDE — GermanyIN — IndiaSA — Saudi ArabiaRU — RussiaSE — Sweden
Impacted Modules
5.3.5
Linked Variations (0)
Variation #TypeApplicationStatusSubmittedApproved